Mylan, Teva settle Copaxone patent fight; ViiV's new Tivicay wins key EU backing;

@FiercePharma: Monday's top story: Who leaked the scary Copaxone numbers? Teva intends to find out. Story | Follow @FiercePharma

@EricPFierce: Any who thinks women aren't controlling the destiny of biopharma would be wrong. Women in Biotech 2013 Report | Follow @EricPFierce

@CarlyHFierce: FDA withdraws restrictions on GSK diabetes drug Avandia - too little, too late? Story | Follow @CarlyHFierce

> Mylan ($MYL) and Teva Pharmaceutical Industries ($TEVA) have come to terms in a patent fight over the latter's multiple sclerosis treatment Copaxone, but those terms weren't disclosed. Report

> ViiV Healthcare's new HIV treatment Tivicay is on track for European approval with new backing from a key committee; the drug launched in the U.S. a few weeks ago. Report

> Hedge fund Elliott International has accumulated control of 25% of the voting rights in Germany-based drugs distributor Celesio, which McKesson ($MCK) is trying to buy for $8.3 billion. Report

> Valeant Pharmaceuticals ($VRX) tapped Ari Kellen to take on the role of executive vice president and company group chairman; he had been a senior partner at McKinsey & Co. Report

> Sun Pharmaceutical stock gained after its subsidiary Taro Pharmaceutical offered to buy back up to $200 million in shares, which would push Sun's effective stake in the Israeli drugmaker to 69%. Report

> A Florida judge upheld the use of a new combination of execution drugs that leaves out the chronically short pentobarbital. Report

Medical Device News

@FierceMedDev: Becton Dickinson boost its quarterly dividend. Item | Follow @FierceMedDev

@MarkHFierce: J&J's $2.5B hip implant settlement offer is already beginning to generate some flack from patients. Story via NYT | Follow @MarkHFierce

> Hospira faces another pump recall over deadly risk. Story

> Patient anger could scuttle J&J's $2.5B hip settlement. Article

> Smith & Nephew's M&A blitz rolls on with Brazilian buy. News

> Dutch VC firm readies $200M fund with an eye on device and Dx investments. More

Biotech News

@FierceBiotech: In our latest report, we feature the top women in the biotech industry. Report | Follow @FierceBiotech

@JohnCFierce: Sanofi might want to reevaluate its cancer strategy about now. Iniparib and fedratinib both written off in '13. More | Follow @JohnCFierce

@DamianFierce: Pro-23andMe petition aims to protect "potentially life-saving diagnostic kits," thereby making the FDA's case. Petition | Follow @DamianFierce

@EmilyMFierce: Harvard study: 30% of all medical tests are probably unnecessary. More | Follow @EmilyMFierce

> Bayer's $2.4B bid to buy Algeta fits neatly with cancer drug strategy. Story

> Sanofi, Merrimack rack up third straight failure for lead cancer drug. Article

> BTG wins FDA OK for varicose vein treatment, projects $500M peak. Story

Pharma Manufacturing News

> JLL expects to buy more CMOs. Story

> Glaxo piles onto API expansion in Scotland. More

> PL Developments, Aaron combine expertise in OTC manufacturing. Article

> Ranbaxy ready to bail on vaccine manufacturing. More

> Bafna draws buyout interest for its European-approved manufacturing. News

Biotech Research News

> Eli Lilly, Project A.L.S. forge preclinical drug discovery pact. News

> Biota halts preclinical antibiotics program as antimicrobial resistance grows. Report

> New targets for Parkinson's revealed in gene network. Story

> Antibiotics may weaken body's response to cancer therapies. Article

> New York Stem Cell Foundation, NIH partner to study rare diseases. Story

And Finally... The number of U.S. ADHD cases leapt by 42% from 2003 to 2012, with 11% of kids aged 4 to 17 years now diagnosed with the disorder. Report